The evaluation of the effect of cinnarizine and betahistine in the treatment of peripheral vertigo

Phase 3

Conditions: H81.3
peripheral vertigo.
Other peripheral vertigo

Registration Number: IRCT20171030037093N16

Lead Sponsor: Vice chancellor for research, Shahrekord University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 170

Inclusion Criteria

Age 18-65 years old
Having symptoms of vertigo for at least two months
Non-sensitivity to cinnarizine and betahistine
Natural Signs and Natural Nerve Findings
Failure to receive vertigo control drugs at least 7 days before
There is no evidence of the causes of central vertigo in a CT scan performed by a patient before the start of the study

Exclusion Criteria

Patients with abnormal vital signs, kidney failure, liver disease, heart disease, active stomach ulcer disease or diabetes
Patients with ulcerative diagnosis of vertigo with central causes
Brain traumatic brain injury
Concomitant use of hypertension drugs such as thiazide, antihistamines, corticosteroids and calcium channel antagonists.
Patients who are being treated for benzodiazepines for any reason
Patients who have received anti-vertigo during the last week
The sensitivity of the drug to cinnarizine and betahistine
Those who are pregnant or breastfeeding
People who are not satisfied with the study

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of vertigo attacks. Timepoint: Patients will be asked one week after the start of the study and 8 weeks after the start of the study. Method of measurement: vertigo symptom scale questionnaire.

Secondary Outcome Measures